Default company panoramic image
Logo

Epitherapeutics ApS

Epitherapeutics is a leading epigenetic drug discovery company with a focus on oncology and with several programs in lead optimization

  • Stage Product In Development
  • Industry Biotechnology
  • Location 2100 Copenhagen, Capital Region of Denmark, Denmark
  • Currency USD
  • Founded October 2008
  • Employees 17
  • Website epitherapeutics.dk

Company Summary

EpiTherapeutics is developing novel innovative cancer drugs based on world leading research by Professor Kristian Helin. EpiTherapeutics' development programs are focused on epigenetic enzymes involved in cancer (KDMs, KMTs).Most progressed program is in late lead optimization. EpiTherapeutics has a strong investor base including Novo Seeds, SEED Capital, Lundbeckfond Emerge, Merck Serono Ventures and Astellas Venture Management.

Team

  • Default avatar
    Martin Bonde
    CEO

    Serial entrepreneur, founded and managed several companies in Denmark and the US (NatImmune A/S, Arpida A/S, Combio A/S, CelTor Inc., Torsana Biosensor)
    Fronted several successful exits over the last decade (NatImmune A/S to IPC, Combio A/S to Arpida AG, Torsana Biosensor A/S to Celtor Inc) as well as heading out-licensing, acquisitions, in-licensing etc.

Advisors

  • Default avatar
    Wiggin&Dana
    Lawyer
    Unconfirmed
    Default avatar
    Ernst&Young
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Novo Seeds, SEED Capital, Lundbeckfond Emerge
    Unconfirmed
    Default avatar
    Merck- Serono Ventures, Astellas Venture
    Unconfirmed